<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04197349</url>
  </required_header>
  <id_info>
    <org_study_id>ALD1910-CLIN-001</org_study_id>
    <secondary_id>18902A</secondary_id>
    <nct_id>NCT04197349</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability and Pharmacokinetics of ALD1910 in Healthy Men and Woman</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Phase 1 Study to Determine the Safety, Tolerability, and Pharmacokinetics of ALD1910, a Humanized Anti-Pituitary Adenylate Cyclase Activating Peptide (PACAP) Monoclonal Antibody</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>H. Lundbeck A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Alder Biopharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>H. Lundbeck A/S</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the safety, tolerability and pharmacokinetics of
      ALD1910, a monoclonal antibody, administered by intravenous infusion and subcutaneous
      injection.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a first-in-humam, randomized, double-blind, placebo-controlled study in a healthy
      population. Up to 7 single ascending doses (cohorts 1 to 7) will be studied to determine the
      safety and tolerability of ALD1910. Approximately 96 healthy male and female participants are
      planned for the study, 64 for Part A and 32 for Part B.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 24, 2019</start_date>
  <completion_date type="Anticipated">July 29, 2020</completion_date>
  <primary_completion_date type="Anticipated">July 29, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with treatment-emergent adverse events</measure>
    <time_frame>From dosing to week 20</time_frame>
    <description>Safety and tolerability based on the safety assessments (clinical safety laboratory tests, vital signs, ECG parameters)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area under the serum concentration-time curve (AUC(0-T))</measure>
    <time_frame>From dosing to week 20</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak serum concentration (Cmax)</measure>
    <time_frame>From dosing to week 20</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clearance (Cl)</measure>
    <time_frame>From dosing to week 20</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity</measure>
    <time_frame>From dosing to week 20</time_frame>
    <description>Number of anti-ALD1910 antibodies (ADA) and characterization of anti-ALD1910 ADA positive responses for neutralizing activity</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">96</enrollment>
  <condition>Migraine</condition>
  <arm_group>
    <arm_group_label>Part A Cohort 1-8</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ALD1910/Placebo; Single Dose IV infusion on Day 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B Cohort 9</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ALD1910/Placebo+Sumatriptan; Single Dose IV infusion on Day 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B Cohort 10</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ALD1910/Placebo; Single dose subcutaneous injection on Day 1</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ALD1910</intervention_name>
    <description>Single Dose IV infusion</description>
    <arm_group_label>Part A Cohort 1-8</arm_group_label>
    <arm_group_label>Part B Cohort 9</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Sumatriptan</intervention_name>
    <description>Single dose subcutaneous injection</description>
    <arm_group_label>Part B Cohort 9</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ALD1910</intervention_name>
    <description>Single dose subcutaneous injection</description>
    <arm_group_label>Part B Cohort 10</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Healthy male or female

          2. All female subjects must have a negative pregnancy test result and subjects to use of
             adequate contraception for the duration of the study.

          3. Body Mass Index (BMI) between 18.0 and 30.0 kg/m2, and a total body weight of 50 to
             100 kg inclusive.

        Exclusion Criteria:

          1. Use of prescription meds, nutritional supplements, OTC medications.

          2. New or unusually strenuous exercise for the duration of the trial.

          3. Current or previous drug or alcohol abuse.

          4. Current, or previous smoker within 12 weeks prior to screening. Causal or social
             smokers are allowed.

          5. Previous treatment or clinical trial with a monoclonal antibody 6 months prior to
             screening.

          6. Current participation in any clinical research study.

          7. ECG QTcF greater than or equal to 450 msec.

          8. Greater than 6.4% glycosylated hemoglobin (HgbA1c) at screening

          9. Fasting blood glucose greater than or equal to 126 mg/dL (7 mmol/L) at screening
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Email contact via H. Lundbeck A/S</last_name>
    <role>Study Director</role>
    <affiliation>LundbeckClinicalTrials@lundbeck.com</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Email contact via . Lundbeck A/S</last_name>
    <phone>+4536301311</phone>
    <email>LundbeckClinicalTrials@lundbeck.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Nucleus Network Pty Ltd</name>
      <address>
        <city>Melbourne</city>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>December 11, 2019</study_first_submitted>
  <study_first_submitted_qc>December 11, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 13, 2019</study_first_posted>
  <last_update_submitted>December 12, 2019</last_update_submitted>
  <last_update_submitted_qc>December 12, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 16, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sumatriptan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

